Vimarsana
Biggest News Aggregation in the World

Simos Simeonidis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Simos Simeonidis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Simos Simeonidis Today - Breaking & Trending Today

Pharmaceutical industry spring summit: Greece at the heart of pharmaceutical innovation - Vimarsana News

Pharmaceutical industry spring summit: Greece at the heart of pharmaceutical innovation

Sofokleous10.gr Pharmaceutical industry spring summit: Greece at the heart of pharmaceutical innovation

SIMOS SIMEONIDIS, PHD JOINS ALLY BRIDGE GROUP AS CO-CEO AND CO-CIO - Vimarsana News

SIMOS SIMEONIDIS, PHD JOINS ALLY BRIDGE GROUP AS CO-CEO AND CO-CIO

NEW YORK, July 21, 2022 /PRNewswire/ --Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical...

SIMOS SIMEONIDIS, PHD JOINS ALLY BRIDGE GROUP AS CO-CEO AND CO-CIO - Vimarsana News

SIMOS SIMEONIDIS, PHD JOINS ALLY BRIDGE GROUP AS CO-CEO AND CO-CIO

NEW YORK, July 21, 2022 /PRNewswire/ --Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical...